Literature DB >> 11147229

The hyper-CVAD regimen in adult acute lymphocytic leukemia.

G Garcia-Manero1, H M Kantarjian.   

Abstract

The regimen of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) has demonstrated significant activity in adult lymphocytic leukemia (ALL) and in other hematologic malignancies, including Burkitt's disease, lymphoblastic lymphoma, mantle cell lymphoma, and multiple myeloma. This article presents the rationale for the development of this regimen, describes the program, summarizes the results of the large clinical trials developed at the University of Texas M. D. Anderson Cancer Center, and discusses strategies to improve the results.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11147229     DOI： 10.1016/s0889-8588(05)70192-1

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  22 in total

1.  Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.

Authors:  Uri Rozovski; Ohad Benjamini; Preetesh Jain; Philip A Thompson; William G Wierda; Susan O'Brien; Jan A Burger; Alessandra Ferrajoli; Stefan Faderl; Elizabeth Shpall; Chitra Hosing; Issa F Khouri; Richard Champlin; Michael J Keating; Zeev Estrov
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

2.  Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies.

Authors:  Rajul K Jain; David S Hong; Aung Naing; Jennifer Wheler; Thorunn Helgason; Nai-Yi Shi; Yash Gad; Razelle Kurzrock
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.

Authors:  Katrien Van Roosbroeck; Francesca Fanini; Tetsuro Setoyama; Cristina Ivan; Cristian Rodriguez-Aguayo; Enrique Fuentes-Mattei; Lianchun Xiao; Ivan Vannini; Roxana S Redis; Lucilla D'Abundo; Xinna Zhang; Milena S Nicoloso; Simona Rossi; Vianey Gonzalez-Villasana; Rajesha Rupaimoole; Manuela Ferracin; Fortunato Morabito; Antonino Neri; Peter P Ruvolo; Vivian R Ruvolo; Chad V Pecot; Dino Amadori; Lynne Abruzzo; Steliana Calin; Xuemei Wang; M James You; Alessandra Ferrajoli; Robert Orlowski; William Plunkett; Tara M Lichtenberg; Ramana V Davuluri; Ioana Berindan-Neagoe; Massimo Negrini; Ignacio I Wistuba; Hagop M Kantarjian; Anil K Sood; Gabriel Lopez-Berestein; Michael J Keating; Muller Fabbri; George A Calin
Journal:  Clin Cancer Res       Date:  2016-11-30       Impact factor: 12.531

4.  Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.

Authors:  Hui Yang; Tapan Kadia; Lianchun Xiao; Carlos E Bueso-Ramos; Koyu Hoshino; Deborah Ann Thomas; Susan O'Brien; Elias Jabbour; Sherry Pierce; Gary L Rosner; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Blood       Date:  2008-12-23       Impact factor: 22.113

Review 5.  Epigenetics of acute lymphocytic leukemia.

Authors:  Guillermo Garcia-Manero; Hui Yang; Shao-Qing Kuang; Susan O'Brien; Deborah Thomas; Hagop Kantarjian
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

6.  Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.

Authors:  Susan O'Brien; Deborah A Thomas; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Hagop Kantarjian
Journal:  Cancer       Date:  2008-10-15       Impact factor: 6.860

7.  The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms.

Authors:  Jew Win Kuan; Kian Meng Chang; Ngee Siang Lau; Purushothaman Visalachy; Sen Mui Tan; Tee Chuan Ong; Anselm Ting Su
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-05       Impact factor: 0.900

Review 8.  Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase.

Authors:  Nicolas Boissel; Leonard S Sender
Journal:  J Adolesc Young Adult Oncol       Date:  2015-09       Impact factor: 2.223

9.  Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia.

Authors:  Hamilton L Gimenes-Teixeira; Antonio R Lucena-Araujo; Guilherme A Dos Santos; Dalila L Zanette; Priscila S Scheucher; Luciana C Oliveira; Leandro F Dalmazzo; Wilson A Silva-Júnior; Roberto P Falcão; Eduardo M Rego
Journal:  Exp Hematol Oncol       Date:  2013-04-08

10.  Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia.

Authors:  A-Reum Han; Kihyun Kim; Jun Ho Jang; Won Seog Kim; Jin Seok Ahn; Chul Won Jung; Mark H Lee; Won Ki Kang
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.